AVANIR Pharmaceuticals Invites Investors to the Lazard Capital Markets Life Sciences Conference Webcast
Posted on: Wednesday, 23 November 2005, 18:00 CST
AVANIR Pharmaceuticals (AMEX: AVN) announced today that its presentation at the Lazard Capital Markets Annual Life Sciences Conference in New York, NY, will be webcast live on November 30th, 2005, at 2:00 p.m. ET. An archived version of the webcast will be available until December 30, 2005.
Live and archived webcasts of the presentation will be accessible through AVANIR's corporate website at http://www.avanir.com. To access the webcasts, log on to AVANIR's site fifteen minutes prior to the presentation to register and download any necessary audio software.
AVANIR Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. AVANIR recently submitted to the FDA its New Drug Application for Neurodex(TM) for the treatment of pseudobulbar affect. Additionally, AVANIR has initiated a phase III clinical trial of Neurodex(TM) for the treatment of diabetic neuropathic pain. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca UK Limited for the treatment of cardiovascular disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate,""anticipate,""believe,""plan" or "expect." The company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.
Source: Business Wire
Related Articles
- ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
- Nursing Research Grants Available to Improve Treatment of Patients With Auto-Immune Diseases and Cancer
- Statement on FDA's Approval of XENAZINE(R) for the Treatment of Chorea Associated With Huntington's Disease
- Seamless Wi-Fi, Inc. Subsidiaries Will Be Presenting Their Products at CES January 7-10, 2008
- Vical Introduces RapidResponse(TM) DNA Vaccine Cell-Free Platform Designed to Accelerate Vaccine Production During Infectious Disease Outbreaks
- World Renowned Scientist to Issue Call to Action for Treatment and Elimination of Neglected Tropical Diseases on May 25, 2007 - Africa Day
- Idenix Announces Data Presentations at the 2007 Digestive Disease Week Meeting
- Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft Vs. Host Disease
- Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft Vs. Host Disease
- Indonesia to Propose for Special Treatment of Agricultural Products
 |
 |
User Comments (0)
RSS Feeds